01.10.2018 14:00 Uhr

AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
AiCuris and Cyclenium signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases

more ...


AiCuris-Team nominated for German Future Prize 2018
•AiCuris team nominated for their project, "Protection in the Absence of the Immune System - a Life-Saving Innovation against Dangerous Viruses"

more ...


AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B
Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

more ...


Approval of MSD’s PREVYMIS™ (letermovir) in Japan triggers
In March the Japanese Ministry of Health, Labor and Welfare (MLHW) granted marketing authorization to MSD for PREVYMIS™ (letermovir)

more ...

18.04.2018 12:00 Uhr

AiCuris and Max Planck Institute of Molecular Physiology
AiCuris and the Max Planck Institute of Molecular Physiology (MPI) in Dortmund, Germany, have entered into a collaborative agreement to identify novel compounds for the treatment of viral and bacterial infections

more ...


AiCuris’ Licensee MSD launches PREVYMIS™ (letermovir) in Germany
AiCuris and MSD celebrate successful partnership in an exclusive media roundtable discussion pointing to the importance of pharma / biotech collaborations in drug development

more ...


Approval of MSD’s PREVYMIS™ (letermovir) by the European Commission triggers the next EUR 30 million milestone payment for AiCuris
EC approval allows for MSD to market this innovative product across Europe

more ...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke
Management Assistant

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com